HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Michael J Mitten Selected Research

Cytostatic Agents

10/2008ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Michael J Mitten Research Topics

Disease

17Neoplasms (Cancer)
04/2021 - 06/2005
4Glioblastoma (Glioblastoma Multiforme)
04/2021 - 01/2016
4Small Cell Lung Carcinoma (Small Cell Lung Cancer)
10/2014 - 06/2005
3Lymphoma (Lymphomas)
02/2013 - 06/2005
2B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
03/2015 - 02/2013
2Multiple Myeloma
10/2010 - 05/2008
2B-Cell Lymphoma (Lymphoma, B Cell)
10/2010 - 05/2008
1Malignant Mesothelioma
10/2020
1Hypoxia (Hypoxemia)
09/2017
1Neutropenia
03/2015
1Thrombocytopenia (Thrombopenia)
10/2014
1Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse)
10/2010
1Mantle-Cell Lymphoma (Lymphoma, Mantle Cell)
10/2010
1Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular)
10/2008
1Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
05/2008
1Weight Loss (Weight Reduction)
06/2005
1Infections
01/2004

Drug/Important Bio-Agent (IBA)

7navitoclaxIBA
03/2015 - 05/2008
4Immunoconjugates (Immunoconjugate)IBA
04/2021 - 01/2016
4Proteins (Proteins, Gene)FDA Link
02/2013 - 06/2005
3depatuxizumab mafodotinIBA
04/2021 - 01/2018
2Temozolomide (Temodar)FDA LinkGeneric
04/2021 - 01/2016
2epidermal growth factor receptor VIIIIBA
04/2021 - 01/2016
2EpitopesIBA
01/2018 - 01/2016
2depatuxizumabIBA
01/2018 - 01/2016
2venetoclaxIBA
03/2015 - 02/2013
2Sirolimus (Rapamycin)FDA Link
10/2008 - 06/2005
1Biomarkers (Surrogate Marker)IBA
04/2021
1ErbB Receptors (EGF Receptor)IBA
04/2021
1AntigensIBA
04/2021
1A-1331852IBA
10/2020
1auristatinIBA
10/2020
1monomethyl auristatin EIBA
01/2018
1monomethylauristatin FIBA
01/2018
1InterleukinsIBA
09/2017
1Cisplatin (Platino)FDA LinkGeneric
01/2017
1ABT-414IBA
01/2016
1Docetaxel (Taxotere)FDA Link
03/2015
1A-1155463IBA
10/2014
1Cyclophosphamide (Cytoxan)FDA LinkGeneric
10/2010
1Rituximab (Mabthera)FDA Link
10/2010
1Bortezomib (Velcade)FDA Link
10/2010
1Vincristine (Oncovin)FDA LinkGeneric
10/2010
1Cytotoxins (Cytolysins)IBA
10/2010
1Etoposide (VP 16)FDA LinkGeneric
10/2010
1Caspase 3 (Caspase-3)IBA
10/2008
1Cytostatic AgentsIBA
10/2008
1Cytochromes c (Cytochrome c)IBA
05/2008
1ABT-737IBA
06/2005
1Paclitaxel (Taxol)FDA LinkGeneric
06/2005
1Phosphotransferases (Kinase)IBA
06/2005
1Glucose (Dextrose)FDA LinkGeneric
06/2005
1N- succinimidyl- 4- ((iodoacetyl)amino)benzoateIBA
01/2004

Therapy/Procedure

8Therapeutics
01/2018 - 06/2005
1Aftercare (After-Treatment)
04/2021
1Withholding Treatment
06/2008
1Oral Administration
05/2008